Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.81 |
| ▸ | MAPT | P10636 | 7/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.81 |
| ▸ | TP53 | P04637 | 6/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.81 |
| ▸ | HPGD | P15428 | 5/20 | 0.81 |
| ▸ | CASP1 | P29466 | 4/20 | 0.81 |
| ▸ | CASP7 | P55210 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 4/20 | 0.81 |
| ▸ | RECQL | P46063 | 3/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.81 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.81 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.81 |
| ▸ | CDK2 | P24941 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fisetin SCHEMBL14697139 | 0.90 | KDM4E (0.69) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL29349742 | 0.90 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL29381611 | 0.90 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL116861 | 0.90 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL39454 | 0.90 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL29394036 | 0.90 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL4263659 | 0.89 | CDK5 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL15676575 | 0.89 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL29437764 | 0.89 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL30626973 | 0.89 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002357-A1 | 4'-SUBSTITUTED ANALOGUES OF FISETIN AND THEIR USE IN THE TREATMENT OF CANCER | JAWAHARLAL NEHRU UNIVERSITY (IN) | 2024-01-04 | — | — | US | disclosed |
| US-20240002357-A1 | 4'-SUBSTITUTED ANALOGUES OF FISETIN AND THEIR USE IN THE TREATMENT OF CANCER | JAWAHARLAL NEHRU UNIVERSITY (IN) | 2024-01-04 | — | — | US | disclosed |
| WO-2022113047-A1 | 4'-SUBSTITUTED ANALOGUES OF FISETIN AND THEIR USE IN THE TREATMENT OF CANCER | STELLENBOSCH UNIVERSITY (ZA) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022113047-A1 | 4'-SUBSTITUTED ANALOGUES OF FISETIN AND THEIR USE IN THE TREATMENT OF CANCER | STELLENBOSCH UNIVERSITY (ZA) | 2022-06-02 | — | — | WO | disclosed |
| US-20080009451-A1 | Applications of kidney secreted bone growth factor and pharmaceutical use of flavonol and flavonol glycosides for stimulating the secretion of kidney secreted bone growth factor | LONG MIAN | 2008-01-10 | — | — | US | disclosed |
| EP-1100539-A2 | COMBINATION OF ACTIVE SUBSTANCES, ESPECIALLY FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC ORGANIC LESIONS AND REPERFUSION SYNDROMES | Vascular Biotech GmbH (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000007578-A2 | COMBINATION OF ACTIVE SUBSTANCES, ESPECIALLY FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC ORGANIC LESIONS AND REPERFUSION SYNDROMES | VASCULAR BIOTECH GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002357-A1 | 4'-SUBSTITUTED ANALOGUES OF FISETIN AND THEIR USE IN THE TREATMENT OF CANCER | FIS1, HNF4A, KRAS | MEN1 1313/4885KMT2A 416/4885CYP3A4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.